# China NMPA Drug Inspection - Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd. - Ginseng

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-xiehecheng-pharmaceutical-pieces-co-ltd/13136ef9-f85b-4c35-a9d5-0256723813be/
Source feed: China

> China NMPA drug inspection for Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd. published January 19, 2018. Drug: Ginseng. The State Administration for Market Regulation (formerly China Food and Drug Administration) issued an announcement on J

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 18 of 2018 from the State Administration of Traditional Chinese Medicine regarding 8 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd.
- Publication Date: 2018-01-19
- Drug Name: Ginseng
- Inspection Finding: Pesticide residue levels not up to standard
- Action Taken: Relevant provincial food and drug administration departments have taken control measures such as sealing and seizing, requiring enterprises to suspend sales and use, recall products, and rectify the situation; in accordance with the "Drug Administration Law of the People's Republic of China," they have initiated investigations into the illegal acts and will make the results public within three months. If the products were indeed produced by the manufacturing enterprise, they will be severely punished.
- Summary: The State Administration for Market Regulation (formerly China Food and Drug Administration) issued an announcement on January 19, 2018, regarding the non-compliance of traditional Chinese medicine decoction pieces. The announcement detailed findings from the China National Institutes for Food and Drug Control, which identified eight batches of products from eight different manufacturers, including Jiangsu Fuyuan Traditional Chinese Medicine Decoction Pieces Co., Ltd. and Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd., as unqualified. The primary issue identified was excessive pesticide residue in ginseng products, failing to meet the standards set forth in the 2015 edition of the Pharmacopoeia of the People's Republic of China. In response to these findings, provincial food and drug administration departments initiated immediate control measures. These included sealing and seizing the substandard products, requiring companies to suspend sales, recall affected batches, and implement corrective actions. Companies were also afforded a process to object to the authenticity of a product, triggering further investigation by regulatory bodies. The State Food and Drug Administration mandated that provincial authorities investigate these illegal acts in accordance with Articles 73, 74, and 75 of the 'Drug Administration Law of the People's Republic of China'. They are required to publicly disclose the outcomes of these investigations within three months, reinforcing the commitment to public health and product quality.

Company: https://www.globalkeysolutions.net/companies/anhui-xiehecheng-pharmaceutical-pieces-co-ltd/7bb8869f-acbe-4bb2-8b6a-a84937c3c64c/